tailieunhanh - Báo cáo khoa học: "Correspondence: Prostatic sarcoma after treatment for rectal cancer"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Correspondence: Prostatic sarcoma after treatment for rectal cancer | World Journal of Surgical Oncology BioMed Central Correspondence Open Access Correspondence Prostatic sarcoma after treatment for rectal cancer Noel J Aherne and Charles M Gillham Address Department of Radiation Oncology St. Luke s Hospital Dublin 6 Ireland Email Noel J Aherne - noelaherne@ Charles M Gillham - cmgillham@ Corresponding author Published 17 February 2008 Received 4 September 2007 World Journal of Surgical Oncology 2008 6 20 doi l477-78l 9-6-20 Accepted 17 February 2008 This article is available from http content 6 1 20 2008 Aherne and Gillham licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Dear Sirs The authors Abbas SM and Hill AG 1 outline their experience of a case of prostatic sarcoma occurring four years post neoadjuvant radiation therapy for primary mid rectal adenocarcinoma. They correctly state that as this second malignancy occurred within the radiation field it meets the criteria for a radiation - induced second malignancy. However it has been noted that while there is no established dose response relationship for sarcoma that they are generally felt to occur within the high dose region. A dose of 4500 cGy seems unlikely to lead to sarcoma formation within such a short time frame. While post radiation sarcomas have commonly been described in the pelvis they more commonly follow high dose 3 Dimensional Conformal Radiation therapy 3DCRT with or without intracavitary brachytherapy doses 7000 cGy in gynecological cancers or in combination with interstitial seed brachytherapy doses 1000 cGy in prostatic malignancy. In contrast primary prostatic sarcoma is a well recognized clinical entity with over 50 cases recorded in the literature 2-4 . While the author s .